Advertisement

Cancer in the Very Elderly and Management

  • Niluja Thiruthaneeswaran
  • Lucinda Morris
  • Jayasingham Jayamohan
Chapter

Abstract

The very elderly population defined as 85 years and over is expected to reach ten million in the USA by 2030, almost double current figures. The risk of cancer increases with age with peak incidence occurring between 65–85 years. The cancer mortality rate increases with age but is not the leading cause of death in the very elderly. Aggressive cancer therapy in older patient ≥85 years would not have been a consideration by many clinicians which is reflected in the age limit of the inclusion criteria of clinical trials in the last 10–20 years. An overwhelming number of trials in oncology have been in the fittest patients and cannot be universally applied to the elderly where a decline in organ function can vary considerably between patients. The comprehensive geriatric assessment (CGA) tool is the most robust method available for assessing global fitness in the elderly to determine the suitability of treatment. The challenge clinicians face is balancing the benefit of treatment against the risk and ensuring elderly patients receive optimal care. This chapter focuses on management of common solid tumours (breast, prostate, lung and colorectal) in the oldest-old and the issues encountered in practice in this population.

Keywords

Cancer Oldest-old Frailty CGA Cancer incidence Octogenarians Nonagenarians Surgery Radiotherapy Chemotherapy 

References

  1. 1.
    Yancik R. Population aging and cancer: a cross-national concern. Cancer J. 2005;11(6):437–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Nolen SC, Evans MA, Fischer A, Corrada MM, Kawas CH, Bota DA. Cancer-incidence, prevalence and mortality in the oldest-old. A comprehensive review. Mech Ageing Dev. 2017;164:113–26.PubMedCrossRefGoogle Scholar
  3. 3.
    Hanson HA, Smith KR, Stroup AM, Harrell CJ. An age-period-cohort analysis of cancer incidence among the oldest old, Utah 1973-2002. Popul Stud (Camb). 2015;69(1):7–22.CrossRefGoogle Scholar
  4. 4.
    Harding C, Pompei F, Wilson R. Peak and decline in cancer incidence, mortality, and prevalence at old ages. Cancer. 2012;118(5):1371–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Linebarger JH, Landercasper J, Ellis RL, Gundrum JD, Marcou KA, De Maiffe BM, et al. Core needle biopsy rate for new cancer diagnosis in an interdisciplinary breast center: evaluation of quality of care 2007-2008. Ann Surg. 2012;255(1):38–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Andersen SL, Terry DF, Wilcox MA, Babineau T, Malek K, Perls TT. Cancer in the oldest old. Mech Ageing Dev. 2005;126(2):263–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Stanta G, Campagner L, Cavallieri F, Giarelli L. Cancer of the oldest old. What we have learned from autopsy studies. Clin Geriatr Med. 1997;13(1):55–68.PubMedCrossRefGoogle Scholar
  8. 8.
    van Heemst D. Biology of cancer and ageing. Eur J Cancer. 2009;45(Suppl 1):414–5.PubMedCrossRefGoogle Scholar
  9. 9.
    de Magalhaes JP. How ageing processes influence cancer. Nat Rev Cancer. 2013;13(5):357–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Participants P, Audisio RA, Pope D, Ramesh HS, Gennari R, van Leeuwen BL, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol. 2008;65(2):156–63.CrossRefGoogle Scholar
  11. 11.
    Ramesh HS, Boase T, Audisio RA. Risk assessment for cancer surgery in elderly patients. Clin Interv Aging. 2006;1(3):221–7.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Leung JM, Dzankic S. Relative importance of preoperative health status versus intraoperative factors in predicting postoperative adverse outcomes in geriatric surgical patients. J Am Geriatr Soc. 2001;49(8):1080–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Goldman L, Caldera DL, Nussbaum SR, Southwick FS, Krogstad D, Murray B, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977;297(16):845–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med. 1981;9(8):591–7.CrossRefGoogle Scholar
  15. 15.
    Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, et al. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2014;112(1):140–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Kimmick GG, Peterson BL, Kornblith AB, Mandelblatt J, Johnson JL, Wheeler J, et al. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol. 2005;23(10):2201–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Siu LL. Clinical trials in the elderly–a concept comes of age. N Engl J Med. 2007;356(15):1575–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, Investigators PI. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266–73.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583–8.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients–an analysis of the medical literature. J Clin Oncol. 2007;25(14):1832–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Rivoirard R, Chargari C, Kullab S, Trone JC, Langrand-Escure J, Moriceau G, et al. Chemotherapy regimen in nonagenarian cancer patients: a bi-institutional experience. Chemotherapy. 2016;61(2):65–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Sud S, Lai P, Zhang T, Clemons M, Wheatley-Price P. Chemotherapy in the oldest old: the feasibility of delivering cytotoxic therapy to patients 80 years old and older. J Geriatr Oncol. 2015;6(5):395–400.PubMedCrossRefGoogle Scholar
  23. 23.
    Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Kim J, Hurria A. Determining chemotherapy tolerance in older patients with cancer. J Natl Compr Cancer Netw. 2013;11(12):1494–502.CrossRefGoogle Scholar
  25. 25.
    Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86.PubMedCrossRefGoogle Scholar
  26. 26.
    Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8(12):1101–15.PubMedCrossRefGoogle Scholar
  28. 28.
    Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Kenis C, Bron D, Libert Y, Decoster L, Van Puyvelde K, Scalliet P, et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol. 2013;24(5):1306–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Droz JP, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol. 2017;72:521.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Morris L, Thiruthaneeswaran N, Lehman M, Hasselburg G, Turner S. Are future radiation oncologists equipped with the knowledge to manage elderly patients with cancer? Int J Radiat Oncol Biol Phys. 2017;98(4):743–7.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Bastiaannet E, Liefers GJ, de Craen AJ, Kuppen PJ, van de Water W, Portielje JE, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat. 2010;124(3):801–7.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Lavelle K, Sowerbutts AM, Bundred N, Pilling M, Degner L, Stockton C, et al. Is lack of surgery for older breast cancer patients in the UK explained by patient choice or poor health? A prospective cohort study. Br J Cancer. 2014;110(3):573–83.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M. Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. Br J Cancer. 2007;96(8):1197–203.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Singh R, Hellman S, Heimann R. The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer. 2004;100(9):1807–13.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003;21(19):3580–7.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Gennari R, Curigliano G, Rotmensz N, Robertson C, Colleoni M, Zurrida S, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer. 2004;101(6):1302–10.PubMedCrossRefGoogle Scholar
  38. 38.
    Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.PubMedCrossRefGoogle Scholar
  40. 40.
    Sweeney C, Schmitz KH, Lazovich D, Virnig BA, Wallace RB, Folsom AR. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst. 2006;98(8):521–9.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    de Haes JC, Curran D, Aaronson NK, Fentiman IS. Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial. Eur J Cancer. 2003;39(7):945–51.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703–20.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–7.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    International Breast Cancer Study G, Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006;24(3):337–44.CrossRefGoogle Scholar
  45. 45.
    Chagpar AB, McMasters KM, Edwards MJ, North American Fareston Tamoxifen Adjuvant T. Can sentinel node biopsy be avoided in some elderly breast cancer patients? Ann Surg. 2009;249(3):455–60.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Early Breast Cancer Trialists' Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRefGoogle Scholar
  47. 47.
    Ebctcg, McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.CrossRefGoogle Scholar
  48. 48.
    Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.CrossRefGoogle Scholar
  49. 49.
    Smith BD, Gross CP, Smith GL, Galusha DH, Bekelman JE, Haffty BG. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006;98(10):681–90.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993;328(22):1587–91.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Deutsch M. Radiotherapy after lumpectomy for breast cancer in very old women. Am J Clin Oncol. 2002;25(1):48–9.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Group ST, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–107.CrossRefGoogle Scholar
  54. 54.
    Group ST, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–41.CrossRefGoogle Scholar
  55. 55.
    Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048–60.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387(10015):229–38.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Blamey RW, Bates T, Chetty U, Duffy SW, Ellis IO, George D, et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer. 2013;49(10):2294–302.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641–8.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Weissberg JB, Prosnitz LR. Treatment of early breast cancer with primary radiation therapy: rationale, results, and techniques. Bull N Y Acad Med. 1982;58(2):203–13.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Price A, Kerr GR, Rodger A. Primary radiotherapy for T4 breast cancer. Clin Oncol (R Coll Radiol). 1992;4(4):217–21.CrossRefGoogle Scholar
  62. 62.
    Bedwinek J, Rao DV, Perez C, Lee J, Fineberg B. Stage III and localized stage IV breast cancer: irradiation alone vs irradiation plus surgery. Int J Radiat Oncol Biol Phys. 1982;8(1):31–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Bedwinek J. Radiation therapy of isolated local-regional recurrence of breast cancer: decisions regarding dose, field size, and elective irradiation of uninvolved sites. Int J Radiat Oncol Biol Phys. 1990;19(4):1093–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol. 2014;32(26):2913–9.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.CrossRefGoogle Scholar
  66. 66.
    Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.PubMedCrossRefGoogle Scholar
  67. 67.
    Fentiman IS, Christiaens MR, Paridaens R, Van Geel A, Rutgers E, Berner J, et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer. 2003;39(3):309–16.PubMedCrossRefGoogle Scholar
  68. 68.
    Mustacchi G, Scanni A, Capasso I, Farris A, Pluchinotta A, Isola G. Update of the phase III trial 'GRETA' of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women. Future Oncol. 2015;11(6):933–41.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg. 2004;91(6):699–704.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review. Br J Cancer. 2007;96(7):1025–9.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Balakrishnan A, Ravichandran D. Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. Br J Cancer. 2011;105(12):1825–9.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Rai S, Stotter A. Management of elderly patients with breast cancer: the time for surgery. ANZ J Surg. 2005;75(10):863–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRefGoogle Scholar
  74. 74.
    Du XL, Xia R, Burau K, Liu CC. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol. 2011;28(Suppl 1):S80–90.PubMedCrossRefGoogle Scholar
  75. 75.
    Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20(24):4636–42.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Klepin HD, Pitcher BN, Ballman KV, Kornblith AB, Hurria A, Winer EP, et al. Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). J Oncol Pract. 2014;10(5):e285–92.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    WHO. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide 2012. World Health Organisation; 2012. Available from: http://globocan.iarc.fr/Default.aspx.
  78. 78.
    CRUK. Prostate cancer statistics: Cancer Research UK; 2014. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer.
  79. 79.
    James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.PubMedCrossRefGoogle Scholar
  81. 81.
    Thompson RH, Slezak JM, Webster WS, Lieber MM. Radical prostatectomy for octogenarians: how old is too old? Urology. 2006;68(5):1042–5.PubMedCrossRefGoogle Scholar
  82. 82.
    Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N, et al. Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. Eur Urol. 2008;54(1):107–16.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004;172(6 Pt 1):2227–31.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Loeb S, Roehl KA, Helfand BT, Catalona WJ. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology. 2008;72(4):887–91.PubMedCrossRefGoogle Scholar
  85. 85.
    Palma D, Senan S. Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. Curr Opin Oncol. 2011;23(2):133–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13(1):43–54.PubMedCrossRefGoogle Scholar
  87. 87.
    Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884–90.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Hoskin P, Misra V, Hopkins K, Holt T, Brown G, Arnott S, et al. SCORAD III: randomized noninferiority phase III trial of single-dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC). J Clin Oncol. 2017;35(15_suppl):LBA10004.CrossRefGoogle Scholar
  90. 90.
    Chow R, Hoskin P, Hollenberg D, Lam M, Dennis K, Lutz S, et al. Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. Ann Palliat Med. 2017;6(2):125–42.PubMedCrossRefGoogle Scholar
  91. 91.
    Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.PubMedCrossRefGoogle Scholar
  92. 92.
    Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD. Lung cancer: principles and practice Lippincott. Philadelphia: Williams & Wilkins; 2000. p. 367–88.Google Scholar
  93. 93.
    Brambilla E, TWLcIWCR, Stewart BW, Wild CP, editors. World cancer report 2014. Lyon: World Health Organization; 2014.Google Scholar
  94. 94.
    Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25(35):5570–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Mery CM, Pappas AN, Bueno R, Colson YL, Linden P, Sugarbaker DJ, et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest. 2005;128(1):237–45.PubMedCrossRefGoogle Scholar
  96. 96.
    Cassidy RJ, Zhang X, Patel PR, Shelton JW, Tian S, Steuer CE, et al. Health care disparities among octogenarians and nonagenarians with stage III lung cancer. J Clin Oncol. 2017;35(15_suppl):e18075.CrossRefGoogle Scholar
  97. 97.
    Sawada S, Komori E, Nogami N, Bessho A, Segawa Y, Shinkai T, et al. Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition. Chest. 2005;128(3):1557–63.PubMedCrossRefGoogle Scholar
  98. 98.
    Firat S, Pleister A, Byhardt RW, Gore E. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol. 2006;29(3):252–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Port JL, Kent M, Korst RJ, Lee PC, Levin MA, Flieder D, et al. Surgical resection for lung cancer in the octogenarian. Chest. 2004;126(3):733–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Matsuoka H, Okada M, Sakamoto T, Tsubota N. Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age. Eur J Cardiothorac Surg. 2005;28(3):380–3.PubMedCrossRefGoogle Scholar
  101. 101.
    Pallis AG, Gridelli C, van Meerbeeck JP, Greillier L, Wedding U, Lacombe D, et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol. 2010;21(4):692–706.PubMedCrossRefGoogle Scholar
  102. 102.
    Pallis AG, Gridelli C, Wedding U, Faivre-Finn C, Veronesi G, Jaklitsch M, et al. Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol. 2014;25(7):1270–83.PubMedCrossRefGoogle Scholar
  103. 103.
    Rivera C, Dahan M, Bernard A, Falcoz PE, Thomas P. Surgical treatment of lung cancer in the octogenarians: results of a nationwide audit. Eur J Cardiothorac Surg. 2011;39(6):981–6.PubMedCrossRefGoogle Scholar
  104. 104.
    Fanucchi O, Ambrogi MC, Dini P, Lucchi M, Melfi F, Davini F, et al. Surgical treatment of non-small cell lung cancer in octogenarians. Interact Cardiovasc Thorac Surg. 2011;12(5):749–53.PubMedCrossRefGoogle Scholar
  105. 105.
    Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol. 2012;30(13):1447–55.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Wisnivesky JP, Halm E, Bonomi M, Powell C, Bagiella E. Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. Am J Respir Crit Care Med. 2010;181(3):264–9.PubMedCrossRefGoogle Scholar
  107. 107.
    Jeremic B, Zimmermann FB, Nieder C, Molls MM. Radiation therapy alone as an alternative to surgery in patients with early stage non-small-cell lung cancer having cardiovascular (and other) comorbidity. Eur J Cardiothorac Surg. 2004;25(2):297.PubMedCrossRefGoogle Scholar
  108. 108.
    Zimmermann FB, Bamberg M, Molls M, Jeremic B. Radiation therapy alone in early stage non-small cell lung cancer. Semin Surg Oncol. 2003;21(2):91–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010;28(35):5153–9.PubMedCrossRefGoogle Scholar
  110. 110.
    Louie AV, Rodrigues GB, Palma DA, Senan S. Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada. Oncologist. 2014;19(8):880–5.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Haasbeek CJ, Palma D, Visser O, Lagerwaard FJ, Slotman B, Senan S. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol. 2012;23(10):2743–7.PubMedCrossRefGoogle Scholar
  112. 112.
    Kang KH, Okoye CC, Patel RB, Siva S, Biswas T, Ellis RJ, et al. Complications from stereotactic body radiotherapy for lung cancer. Cancers (Basel). 2015;7(2):981–1004.CrossRefGoogle Scholar
  113. 113.
    Ricardi U, Badellino S, Filippi AR. Stereotactic radiotherapy for early stage non-small cell lung cancer. Radiat Oncol J. 2015;33(2):57–65.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Hayashi S, Tanaka H, Kajiura Y, Ohno Y, Hoshi H. Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer. Radiat Oncol. 2014;9:138.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Videtic GM, Woody NM, Reddy CA, Stephans KL. “Never too old”: a single-institution experience of stereotactic body radiotherapy for patients 90 years and older with early stage lung cancer. Pract Radiat Oncol. 2017;7(6):e543–9.PubMedCrossRefGoogle Scholar
  117. 117.
    The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91(1):66–72.CrossRefGoogle Scholar
  118. 118.
    Kawaguchi T, Tamiya A, Tamura A, Arao M, Saito R, Matsumura A, et al. Chemotherapy is beneficial for elderly patients with advanced non-small-cell lung cancer: analysis of patients aged 70-74, 75-79, and 80 or older in Japan. Clin Lung Cancer. 2012;13(6):442–7.PubMedCrossRefGoogle Scholar
  119. 119.
    Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2191–7.PubMedCrossRefGoogle Scholar
  120. 120.
    Brown TPG, Boland A, Oyee J, Tudur-Smith C. Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. Health Technol Assess. 2013;17(6):1–99.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Langer CJ. The “lazarus response” in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol. 2009;27(9):1350–4.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012;7(12):1815–22.PubMedCrossRefGoogle Scholar
  123. 123.
    Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012;7(9):1417–22.PubMedCrossRefGoogle Scholar
  124. 124.
    Asami K, Koizumi T, Hirai K, Ameshima S, Tsukadaira A, Morozumi N, et al. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer. 2011;12(6):387–92.PubMedCrossRefGoogle Scholar
  125. 125.
    Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27(9):1394–400.PubMedCrossRefGoogle Scholar
  126. 126.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016;5:CD010383.Google Scholar
  127. 127.
    Census Bureau U. National population projections tables: US Census Bureau; 2014. Available from: https://www.census.gov/data/tables/2014/demo/popproj/2014-summary-tables.html.
  128. 128.
    Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008;9(5):494–501.PubMedCrossRefGoogle Scholar
  129. 129.
    Rijkmans EC, Cats A, Nout RA, van den Bongard D, Ketelaars M, Buijsen J, et al. Endorectal brachytherapy boost after external beam radiation therapy in elderly or medically inoperable patients with rectal cancer: primary outcomes of the phase 1 HERBERT study. Int J Radiat Oncol Biol Phys. 2017;98(4):908–17.PubMedCrossRefGoogle Scholar
  130. 130.
    Corner C, Bryant L, Chapman C, Glynne-Jones R, Hoskin PJ. High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy. 2010;9(1):66–70.PubMedCrossRefGoogle Scholar
  131. 131.
    Bokkerink GM, de Graaf EJ, Punt CJ, Nagtegaal ID, Rutten H, Nuyttens JJ, et al. The CARTS study: chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery. BMC Surg. 2011;11:34.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Twelves C, Wong A, Nowacki MP, Abt M, Burris HI, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–704.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Meyers BM, Cosby R, Quereshy F, Jonker D. Adjuvant chemotherapy for stage II and III colon cancer following complete resection: a cancer care Ontario systematic review. Clin Oncol (R Coll Radiol). 2017;29(7):459–65.CrossRefGoogle Scholar
  135. 135.
    Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol. 2015;26(4):715–24.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091–7.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002;136(5):349–57.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17(8):2412–8.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Adam R, Frilling A, Elias D, Laurent C, Ramos E, Capussotti L, et al. Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010;97(3):366–76.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Niluja Thiruthaneeswaran
    • 1
    • 2
  • Lucinda Morris
    • 3
  • Jayasingham Jayamohan
    • 3
  1. 1.The University of SydneySydneyAustralia
  2. 2.University of ManchesterManchesterUK
  3. 3.Crown Princess Mary Cancer CenterWestmeadAustralia

Personalised recommendations